← FDA DRUG APPROVALS

FDA ANDA · ANDA203508

LISINOPRIL

Sponsor: INVAGEN PHARMS

APPLICATION
ANDA203508
TYPE
ANDA
ORIGINAL APPROVAL
2013-10-29
LATEST ACTION
2020-09-17
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

LISINOPRILPrescription
LISINOPRIL 20MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 5MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 30MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 10MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 2.5MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 40MG · TABLET · ORAL

Approval history

2020-09-17Labeling · Supplement 6 · standardAP
2020-09-17Labeling · Supplement 15 · standardAP
2016-02-18Labeling · Supplement 5 · standardAP
2015-06-02Labeling · Supplement 2 · standardAP
2015-06-02Labeling · Supplement 3 · standardAP
2013-10-29UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →